Byrom N A, Campbell M A, Dean A J, Timlin D M, Volkers C, Bodenham D C, Hobbs J R
Cancer Treat Rep. 1978 Nov;62(11):1769-74.
E rosette-forming (T) lymphocytes and surface immunoglobulin-bearing lymphocytes were estimated in 85 patients with malignant melanoma. The melanoma patient group had lower mean levels of T lymphocytes and higher mean levels of immunoglobulin-bearing (? B) lymphocytes than did normal subjects. The absolute and percentage depressions of T-cell levels in the melanoma patients were stage-related, as was the depression of total lymphocyte and B-lymphocyte levels. The T lymphopenia in the melanoma patients could, in vitro, be partially abolished by fetal calf serum (as used in many E rosetting methods), and could be totally abolished by thymosin fraction 5 (Hoffmann-La Roche) at optimum concentration. In view of the ability of thymosin to restore T cells to normal levels in all of the T-lymphopenic patients, a clinical trial of this hormone in selected melanoma patients of all stages appears to be warranted.
对85例恶性黑色素瘤患者的E玫瑰花结形成（T）淋巴细胞和表面带有免疫球蛋白的淋巴细胞进行了评估。与正常受试者相比，黑色素瘤患者组的T淋巴细胞平均水平较低，而表面带有免疫球蛋白的（B）淋巴细胞平均水平较高。黑色素瘤患者T细胞水平的绝对降低和百分比降低与分期有关，总淋巴细胞和B淋巴细胞水平的降低也与分期有关。黑色素瘤患者的T淋巴细胞减少在体外可被胎牛血清（许多E玫瑰花结形成方法中使用）部分消除，在最佳浓度下可被胸腺素5（霍夫曼-罗氏公司）完全消除。鉴于胸腺素能使所有T淋巴细胞减少的患者的T细胞恢复到正常水平，因此对各期选定的黑色素瘤患者进行这种激素的临床试验似乎是有必要的。
